The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …

Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …

The medical history of cancer began millennia ago. Historical findings of patients with
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …

Because dysregulation and mutations of protein kinases play causal roles in human
disease, this family of enzymes has become one of the most important drug targets over the …

The epidermal growth factor receptor (EGFR) is one of most potent oncogenes that are
commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been …

The monovalent methyl group is derived from methane through the removal of a hydrogen
atom, 1 and its etymology is directly related to the discovery of methanol. 2 The first reports …

Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR
is involved in several cancer developments, including NSCLC. The EGFR pathway …

ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the
expression or activation of epidermal growth factor receptor and ERBB2 are altered in many …

Resistance to chemotherapy limits the effectiveness of anti‐cancer drug treatment. Tumours
may be intrinsically drug‐resistant or develop resistance to chemotherapy during treatment …

Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for
regulating tumorigenesis and cell survival and may be important in the development and …